The Retinitis Pigmentosa (Retinitis) drugs in development market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Retinitis Pigmentosa (Retinitis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued products.
GlobalData tracks 132 drugs in development for Retinitis Pigmentosa (Retinitis) by 110 companies/universities/institutes. The top development phase for Retinitis Pigmentosa (Retinitis) is preclinical with 73 drugs in that stage. The Retinitis Pigmentosa (Retinitis) pipeline has 115 drugs in development by companies and 17 by universities/ institutes. Some of the companies in the Retinitis Pigmentosa (Retinitis) pipeline products market are: Beijing Chinagene Tech, SparingVision and Opus Genetics.
The key targets in the Retinitis Pigmentosa (Retinitis) pipeline products market include Rhodopsin, X Linked Retinitis Pigmentosa GTPase Regulator, and Usherin.
The key mechanisms of action in the Retinitis Pigmentosa (Retinitis) pipeline product include Rhodopsin Activator with eight drugs in Phase III. The Retinitis Pigmentosa (Retinitis) pipeline products include ten routes of administration with the top ROA being Intravitreal and 16 key molecule types in the Retinitis Pigmentosa (Retinitis) pipeline products market including Gene Therapy, and Small Molecule.
Retinitis Pigmentosa (Retinitis) overview
Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance.
For a complete picture of Retinitis Pigmentosa (Retinitis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
